Similar articles

• Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

  Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Shariat SF, et al. J Clin Oncol. 2007 Feb 1;25(4):349-55. doi: 10.1200/JCO.2006.05.6853. J Clin Oncol. 2007. PMID: 17264329
• Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

  Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF. Gupta A, et al. Eur Urol. 2009 May;55(5):1124-33. doi: 10.1016/j.eururo.2008.06.054. Epub 2008 Jun 23. Eur Urol. 2009. PMID: 18585843
• Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.

  Milanese G, Dellabella M, Fazioli F, Pierpaoli E, Polito M, Siednius N, Montironi R, Blasi F, Muzzonigro G. Milanese G, et al. J Urol. 2009 Mar;181(3):1393-400. doi: 10.1016/j.juro.2008.10.147. Epub 2009 Jan 20. J Urol. 2009. PMID: 19157433
• Serum markers for prostate cancer: a rational approach to the literature.

  Steuber T, O'Brien MF, Lilja H. Steuber T, et al. Eur Urol. 2008 Jul;54(1):31-40. doi: 10.1016/j.eururo.2008.01.034. Epub 2008 Jan 22. Eur Urol. 2008. PMID: 18243505 Review.
• Evolving role of uPA/uPAR system in human cancers.

  Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Dass K, et al. Cancer Treat Rev. 2008 Apr;34(2):122-36. doi: 10.1016/j.ctrv.2007.10.005. Epub 2007 Dec 26. Cancer Treat Rev. 2008. PMID: 18162327 Review.